10-Q quarterly report · filed Nov 9, 2026

MBX Biosciences, Inc. (MBX) Q3 2026 10-Q Quarterly Report

Short answer

MBX Biosciences, Inc. (MBX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$62M
−188.7% YoY · −68.3% QoQ
EPS (diluted)
−$1.29
−104.8% YoY · −63.3% QoQ

Source: XBRL data from the MBX Biosciences, Inc. (MBX) Q3 2026 10-Q on SEC EDGAR. USD.

MBX Biosciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Product revenue $0, unchanged YoY, no approved products or sales
  • Net loss $62.4M vs $21.6M YoY, operating margin not applicable
  • R&D $32.0M vs $19.3M, canvuparatide largest program at $13.6M
  • Cash, equivalents and securities $481.6M vs $373.7M; operating cash use $77.7M
  • Outlook: funding projected into 2029, expenses rising with Phase 3 and obesity pipeline development

Risk Factors

  • No material changes to previously disclosed risk factors in the 2025 Annual Report
  • Business, prospects, operating results and financial condition could suffer materially
  • Common-stock trading price could decline, risking partial or total investment loss
  • Additional risks currently unknown or deemed immaterial could adversely affect the business

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other MBX Biosciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.